100.00% -64.97

Alpine Immune Sciences Inc (ALPN)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Alpine Immune Sciences Inc Stock (ALPN) Company Profile

Alpine Immune Sciences Inc

206-788-4545

201 Elliott Avenue West, Suite 230, Seattle, WA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

ALPN's Discussions on Twitter

Alpine Immune Sciences Inc Stock (ALPN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-10-18	Eingeleitet	Berenberg	Buy
2023-10-17	Eingeleitet	Berenberg	Buy
2023-10-05	Eingeleitet	RBC Capital Mkts	Outperform
2023-06-26	Fortgesetzt	Oppenheimer	Outperform
2023-01-19	Eingeleitet	Morgan Stanley	Overweight
2022-11-21	Eingeleitet	SVB Leerink	Outperform
2020-12-21	Eingeleitet	H.C. Wainwright	Buy
2020-08-26	Eingeleitet	Cowen	Outperform

Alle ansehen

Alpine Immune Sciences Inc Aktie (ALPN) Neueste Nachrichten

Finanzdaten der Alpine Immune Sciences Inc-Aktie (ALPN)

Alpine Immune Sciences Inc (ALPN)

Alpine Immune Sciences Inc Stock (ALPN) Company Profile

Alpine Immune Sciences Inc Stock (ALPN) Upgrades & Downgrades

Alpine Immune Sciences Inc Aktie (ALPN) Neueste Nachrichten

MyMyasthenia Gravis Clinical Trial Analysis, 2024 Updates | - openPR

Big Drugmakers Are Clinching Smaller Deals - The Wall Street Journal

Big Drugmakers Are Clinching Smaller Deals - Yahoo Finance

Alpine (ALPN) Surges 37% on $4.9B Buyout Offer From Vertex - MSN

Vertex Lifts Revenue Outlook on Growth of Cystic Fibrosis Drugs - Bloomberg

Vertex Pharma raises annual revenue forecast on strong demand for its cystic fibrosis treatments - Yahoo Finance

Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune - MSN

Vertex enters into a definitive agreement to acquire Alpine Immune Sciences - World Business Outlook

Even though Alpine Immune Sciences (NASDAQ:ALPN) has lost US$39m market cap in last 7 days, shareholders are still up 200% over 3 years - Yahoo New Zealand News

Fastest Growing Public Companies in Washington State - The Business Journals

Vertex Pharmaceuticals reports $4.4 billion R&D expense post-acquisition - Investing.com

Even though Alpine Immune Sciences (NASDAQ:ALPN) has lost US$39m market cap in last 7 days, shareholders are ... - Yahoo New Zealand News

Has SiBone (SIBN) Outpaced Other Medical Stocks This Year? - Yahoo Lifestyle Singapore

Esperion Therapeutics (ESPR) Moves 6.5% Higher: Will This Strength Last? - Yahoo Lifestyle Singapore

Here's Why You Should Invest in Alpine (ALPN) Stock Now - Yahoo Lifestyle UK

Alpine Immune Sciences (NASDAQ:ALPN) jumps 12% this week, taking three-year gains to 96% - Yahoo Sport Australia

Biopharma index outpaces market benchmarks with an 8% rise - BioWorld Online

Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Sport Australia

Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Movies UK

Alpine Immune Sciences And Abbvie Announce Option And License Agreement For Development And Commercialization Of ALPN-101 - Reuters

Biogen’s HI-Bio Buy Is Latest Biopharma Spending Spree in Projected $257B Immunology Market - BioSpace

Rafferty Asset Management LLC Purchases Shares of 80162 Alpine Immune Sciences, Inc. (NASDAQ:ALPN) - Defense World

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Given Consensus Rating of “Hold” by Brokerages - Defense World

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Is a Surprise Coming for Alpine Immune Sciences (ALPN) This Earnings Season? - Yahoo Movies UK

Alpine Immune Sciences, Inc. (ALPN) Moves 9.5% Higher: Will This Strength Last? - Yahoo Singapore News

Swiss National Bank Grows Position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) - Defense World

Trexquant Investment LP Purchases 25202 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) - Defense World

Alpine Immune (ALPN) Stock Up 19% MTD, Will the Uptick Continue? - Yahoo Movies UK

Franklin Resources Inc. Acquires Shares of 1220333 Alpine Immune Sciences, Inc. (NASDAQ:ALPN) - Defense World

BNP Paribas Financial Markets Has $2.04 Million Stock Position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) - MarketBeat

BNP Paribas Financial Markets Buys 93423 Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) - Defense World

Alpine Immune Sciences, Inc. (ALPN) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Lifestyle Australia

Vertex Pharma's $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says - MSN

Fenwick Represents Alpine Immune Sciences in its Acquisition by Vertex Pharmaceuticals - Fenwick & West LLP

How To Trade (ALPN) - Stock Traders Daily

Jump Financial LLC Takes Position in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) - MarketBeat

Alpine Immune jumps on report of takeover interest - MSN

Jump Financial LLC Invests $1.06 Million in Alpine Immune Sciences, Inc. (NASDAQ:ALPN) - Defense World

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Shares Acquired by New York State Common Retirement Fund - Defense World

Wedbush Reiterates "Neutral" Rating for Alpine Immune Sciences (NASDAQ:ALPN) - MarketBeat

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

What 11 Analyst Ratings Have To Say About Alpine Immune SciencesAlpine Immune Sciences (NASDAQ:ALPN) - Benzinga

What 11 Analyst Ratings Have To Say About Alpine Immune Sciences - Quantisnow

Alpine Immune Sciences (NASDAQ:ALPN) Reaches New 12-Month High at $64.96 - MarketBeat

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Sees Significant Drop in Short Interest - MarketBeat

Alpine Immune Sciences, Inc. (ALPN) Earnings Expected to Grow: What to Know Ahead of Q3 Release - Yahoo Movies UK

Alpine Immune Sciences (NASDAQ:ALPN) Sees Strong Trading Volume - Defense World

Strength Seen in Alpine Immune Sciences, Inc. (ALPN): Can Its 7.5% Jump Turn into More Strength? - Yahoo Lifestyle UK

Alpine Immune Sciences Inc (ALPN) Reports Q1 2024 Financials Amid Pending Acquisition by Vertex ... - Yahoo Finance

Alpine Immune stock ticks higher as HSR waiting period for Vertex Pharma deal expires - Seeking Alpha

Finanzdaten der Alpine Immune Sciences Inc-Aktie (ALPN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie ALPN